ECOG-ACRIN Cancer Research Group

The post ECOG-ACRIN vice chair Dr. Al Benson discusses the evolving role of first-line immunotherapy for advanced anal cancer, referencing the InterAACT-2 and EA2176 trials appeared first on ECOG-ACRIN Cancer Research Group .

The post Group co-chair Dr. Mitchell Schnall named a health system chief digital officer to know in 2026 appeared first on ECOG-ACRIN Cancer Research Group .

The post The Winter 2026 advocacy blog Considering Clinical Trials is now available appeared first on ECOG-ACRIN Cancer Research Group .

The post Natasha Edwin, MD, community co-chair of the ECOG-ACRIN Myeloma Committee, highlights why patients in rural areas need access to quality clinical trials appeared first on ECOG-ACRIN Cancer Research Group .

The post ECOG-ACRIN legacy lung cancer studies E1594 and E5508 cited in ASCO Living Guideline 2026.3.0 , therapy for stage 4 NSCLC without driver alterations appeared first on ECOG-ACRIN Cancer Research Group .

The post The January 2026 News from ECOG-ACRIN blog is now available appeared first on ECOG-ACRIN Cancer Research Group .

The post Press Release: New England Journal of Medicine publishes phase 3 PATINA (PrECOG PrE0111) trial data demonstrating a significant progression-free survival benefit with palbociclib in metastatic HR+, HER2+ breast cancer appeared first on ECOG-ACRIN Cancer Research Group .

The post ECOG-ACRIN study identifies high rates of vulnerability in AML patients aged 60 years or older appeared first on ECOG-ACRIN Cancer Research Group .

The post WATCH: Drs. Jen Specht and Heather Jacene discuss the FEATURE (EA1183) trial results…a game-changer for bone-dominant metastatic breast cancer appeared first on ECOG-ACRIN Cancer Research Group .

The post AI models advance individualized breast cancer recurrence risk assessments appeared first on ECOG-ACRIN Cancer Research Group .